BPC-157 vs Pentadeca Arginate
An evidence-first, side-by-side comparison. We compare what the research supports — not marketing claims.
Last updated
Evidence grade
Animal
Theoretical
What that means
Preclinical evidence from animal models only — not yet shown in humans.
Mechanistically plausible but not yet demonstrated in any living system.
Status
Research compound
Research compound
Mechanism
A stable 15–amino-acid sequence pulled from a protein found in human gastric juice. In rodents it seems to speed healing by recruiting new blood vessels and driving soft-tissue repair, and by keeping tendon and gut cells alive and migrating where they are needed. Exactly how it pulls this off is still being worked out — and none of it has been confirmed in humans.
Pentadeca Arginate takes the BPC-157 peptide — the same 15–amino-acid backbone — and pairs it with an arginate salt plus extra arginine, tweaks meant to make it more stable and soluble. The pitch is that it should act like BPC-157, driving angiogenesis and tissue repair, while being easier to formulate. Worth stating plainly: that mechanism is inherited from BPC-157 by analogy. It has not been shown for PDA itself.
Goals
Tendon & ligament repair, Gut healing, Muscle recovery
Tendon & ligament repair, Gut healing, Muscle recovery
Key risks
- No published human RCTs — efficacy in people is unproven
- No long-term human safety data; effects of chronic dosing are unknown
- Sold "for research use only," so purity, dose accuracy, and contamination vary by source
- No published peer-reviewed studies of PDA specifically — efficacy is unproven
- No human or independent safety data at all
- Benefits are extrapolated from a parent compound that is itself animal-only
Regulatory
Sold "for research use only" — not approved for human consumption.
Sold "for research use only" — not approved for human consumption.